Search Results
Your search for ASCO matches 21586 pages
Showing 17651 - 17700GeparSixto Study Finds Benefit for Neoadjuvant Carboplatin in Triple-negative Breast Cancer
In patients with triple-negative breast cancer, the addition of carboplatin significantly improved the rate of pathologic complete response after neoadjuvant chemotherapy in a study by the German Breast Group (GBG)/Gynecologic Oncology Working Group–Breast (AGO-B) reported at the 2013 ASCO Annual...
Molecular Tests and Precision Medicine: Not So Fast Now!
The era of the application of genomic, proteomic, and a host of other “omic” analyses to guide decision-making in the therapeutic selection of drugs and biologics is now a key part of cancer care. Medical practice is working to keep up with the scientific advances, evaluate them, and add a variety...
Oncologists Speak Out Against the High Cost of Cancer Drugs
That the United States spends twice as much on health care than other industrialized countries—about $2.8 trillion in 2012—without reaping appreciably better outcomes1 is not news. The topic has been dissected on the front pages of leading newspapers for years and was the subject of the entire...
Expert Point of View: Tim Maughan, MD
Maintenance treatment with capecitabine plus bevacizumab can be considered in clinical practice, according to Tim Maughan, MD, Professor of Clinical Oncology at Oxford University in the United Kingdom, who discussed CAIRO3 at the session. He said that approximately 60% of patients with metastatic...
Maintenance Treatment Delays Progression in Metastatic Colorectal Cancer
For patients with unresectable metastatic colorectal cancer, maintenance treatment with capecitabine (Xeloda) and bevacizumab (Avastin) significantly delayed disease progression and improved overall survival in the phase III CAIRO3 study by the Dutch Colorectal Cancer Group. Miriam Koopman, MD,...
Role of Erlotinib in EGFR Wild-Type Lung Cancer
I welcomed Matthew Stenger’s Journal Spotlight on the TAILOR trial in the August 15 issue of The ASCO Post (“Docetaxel Superior to Erlotinib in Second-Line Treatment of Advanced Non–Small Cell Lung Cancer With Wild-Type EGFR”). The trial was recently published online in Lancet Oncology,1 and...
Expect Questions From Patients About Active Surveillance
While National Comprehensive Cancer Network (NCCN) practice guidelines for prostate cancer advise that active surveillance is usually appropriate for men with very low-risk prostate cancer and a life expectancy ≤ 20 years, a Johns Hopkins study suggests that outcomes for African American men...
Active Surveillance of Very Low-Risk Prostate Cancer Might Not Be Suitable Option for African American Men
African American men with prostate cancer that meets current criteria for very low-risk disease might actually be harboring larger and more aggressive tumors that make active surveillance a less viable option, according to the results of a study published online in the Journal of Clinical Oncology1 ...
Ginseng
Guest Editor Integrative Oncology is guest edited by Barrie R. Cassileth, MS, PhD, Chief of the Integrative Medicine Service and Laurance S. Rockefeller Chair in Integrative Medicine at Memorial Sloan-Kettering Cancer Center, New York. The Integrative Medicine Service at Memorial Sloan-Kettering...
Oncology Meetings
September Georgia Society of Clinical Oncology 2013 GASCO Annual MeetingSeptember 6 • Atlanta, GeorgiaFor more information: www.gasco.us SGI Summit Turkey 2013: Innovations in Obstetrics and GynecologySeptember 6-8 • Istanbul, TurkeyFor more information: www.sgiturkey2013.org/ Breast Cancer...
Combining Community Practice and Health Policy Advocacy
Barbara L. McAneny, MD, is a board-certified medical oncologist/hematologist with a robust community practice in Albuquerque, New Mexico. Dr. McAneny, who has held many leadership roles in oncology associations, became a delegate to the American Medical Association (AMA) from ASCO in 2002, was...
ASH Announces 2013 Honorific Award Recipients
The American Society of Hematology (ASH) announced the seven scientists who have received 2013 Honorific Awards for their significant contributions to the understanding and treatment of hematologic diseases. The Honorific Awards are the Society’s most prestigious awards. This year’s awards will be...
ASCO University® Appoints First Editor-in-Chief
ASCO has appointed Daniel G. Haller, MD, as the first Editor-in-Chief of ASCO University®, an eLearning center designed to serve as the educational home for physicians, nurses, advanced practice providers, and patient educators at every stage of their careers. As head of the editorial board, Dr....
What the Latest Breast Cancer News Means for Patients
Direct your patients to www.cancer.net/breastsymposium to read patient-friendly summaries that explain the research highlighted at the 2013 Breast Cancer Symposium and provide a list of questions to ask their doctors and additional resources to learn more. Also, your patients can listen to a...
ASCO Challenges Its Members to Double Their Impact During the Month of September
For the entire month of September, donors to the Conquer Cancer Foundation of the American Society of Clinical Oncology have the opportunity to double their impact through a matching gift from an anonymous individual donor. From September 1 to 30, 2013, all donations—whether made online, through...
Legislative Endorsement Update From ASCO
ASCO recently announced its endorsement of the Tobacco Tax Equity Act of 2014 (S. 194), which would close tax loopholes that allow tobacco companies to avoid the federal cigarette tax by making taxes on pipe tobacco equivalent to cigarette tobacco. “Raising tobacco taxes is one of the most...
Conquer Cancer Foundation Donor and ASCO Member Denis Hammond, MD: Spreading the Word to Help Conquer Cancer
Oncology care professionals answer hundreds of questions from patients and their families every day. Over the course of months and years doctors and nurses address everything from medical questions about drug regimens and side effects, to personal questions about how cancer may affect work or...
ASCO Examines the Future of Cancer Care Over the Next 2 Decades
While the many scientific advances over the past 50 years have led to improved outcomes for millions of patients with cancer—increasing the number of survivors from just 3 million in the 1970s to nearly 14 million today—the next 20 years promise to bring even greater opportunities to improve the...
Dr. Julie Vose Finds the Best of Both Worlds—Patient Care and Cutting-Edge Research—in Academic Medicine
Julie M. Vose, MD, MBA, is the Neumann M. and Mildred E. Harris Professor and Chief of the Division of Hematology/Oncology at the University of Nebraska Medical Center. She grew up in Mitchell, South Dakota, a small town nestled on the banks of the James River. Mitchell is home to the Corn Palace,...
Enhanced Treatment, Surveillance Needed for Patients With BRAF-Mutant Melanoma to Prevent Secondary Cancers
Researchers at Moffitt Cancer Center suggest secondary cancers seen in melanoma patients who are being treated for a BRAF gene mutation may require new strategies, such as enhanced surveillance and combining BRAF inhibitor therapy with other inhibitors, especially as they become more widely used....
FDA Approves First Rapid Diagnostic Test to Detect Both HIV-1 Antigen and HIV-1/2 Antibodies
The U.S. Food and Drug Administration (FDA) approved the first rapid human immunodeficiency virus (HIV) test for the simultaneous detection of HIV-1 p24 antigen as well as antibodies to both HIV-1 and HIV-2 in human serum, plasma, and venous or fingerstick whole blood specimens. Approved for use as ...
Non–Small Cell Lung Cancer Maintenance Therapy: None, Single Agent, Multiple Agents?
Barlesi et al have reported results of a randomized trial comparing bevacizumab (Avastin) vs pemetrexed (Alimta)/bevacizumab as maintenance therapy in patients with stage IV nonsquamous cell non–small cell lung cancer (NSCLC). It is important to consider their observations in relation to data from...
Pattern in Lung Cancer Pathology May Predict Recurrence After Surgery
A new study by thoracic surgeons and pathologists at Memorial Sloan-Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence. Knowing that this feature exists in a tumor’s pathology could be an important...
Olaparib Shows Robust Progression-Free Survival Benefit in Patients With BRCA Mutations
Maintenance therapy with olaparib extended progression-free survival and the time to disease progression after a second subsequent therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation, according to an updated analysis of Study 19 presented at the 2013 ASCO...
Researchers Identify Gene Variations in Lung Cancer Patients That May Help Predict an Individual's Treatment Response
Researchers at the Moffitt Cancer Center have identified four inherited genetic variants in patients with non–small cell lung cancer that can help predict survival and treatment response. Their findings, published in Carcinogenesis,1 could help lead to more personalized treatment options and...
Paul A. Bunn, Jr, MD, Offers Insights About a Hopeful Era in Lung Cancer Treatment
The treatment of non–small cell lung cancer (NSCLC) is rapidly evolving as molecular targets are being refined and targeted drugs are designed to combat acquired resistance. In his State of the Art Lecture at the 14th International Lung Cancer Congress, Dr. Bunn, Professor of Medicine and the James ...
Will Funding for Lung Cancer Ever Improve?
Lung cancer is the most common cause of cancer-related death in the world. In the United States alone, an estimated 228,190 new cases of lung cancer and 159,480 deaths from lung cancer will occur in 2013. These are alarming statistics when compared to the next four common causes of cancer-related...
Access to and Appropriate Use of Oncology Drugs Called Into Question by ASCO Studies
Studies presented at this year’s ASCO Annual Meeting suggest that despite the wealth of amazing oncolytics on the market, drug shortages persist, drug substitutions are common, off-label use of drugs occurs frequently, and patients find their costs burdensome. Drug Shortage Persists The shortage of ...
Addressing the Key Clinical Questions in Advanced Melanoma
At the 3rd Annual World Cutaneous Malignancies Congress, in La Jolla, California, Steven J. O’Day, MD, Director of Clinical Research at the Beverly Hills Cancer Center and Adjunct Member of the John Wayne Cancer Institute, Los Angeles, addressed what he labeled the “key clinical questions” about...
FDA on CLL Drug Approval and Expanded Access
The ASCO Post article, “Ibrutinib CLL Trial: Where is the Equipoise?” published in May 2013, inaccurately conveyed that the Food and Drug Administration (FDA) requires an improvement in overall survival for chronic lymphocytic leukemia (CLL) drug approval and opposes allowing crossover in the...
Pharmacyclics' Reply
We acknowledge the letters submitted to The ASCO Post from a patient advocate and a chronic lymphocytic leukemia (CLL) patient enrolled on the RESONATE study (PCYC-1112-CA). At Pharmacyclics, we are committed to adhering to high scientific and ethical standards as we strive to develop novel...
Clinical Trials, Crossover, and Clinical Equipoise: An Advocate's Perspective
In a previous issue of The ASCO Post, Dr. Susan O’Brien wrote, “It is my understanding that the FDA strongly opposed allowing crossover [in the RESONATE trial]. I presume that is because the FDA also wants to see if there is a survival advantage.”1 The lack of crossover seems a valid concern to me...
Clinical Trials, Crossover, and Clinical Equipoise: A Patient's Perspective
I am writing with regard to two articles on the ethical imperative of clinical equipoise written by Susan O’Brien, MD, and Stephen J. Schuster, MD, and published recently in The ASCO Post.1,2 I was a victim of Pharmacyclics’ policies during one of their randomized ibrutinib trials (PCI-32765)...
Preventing Tobacco Use in Children
The U.S. Preventive Services Task Force recently released its final recommendation statement on primary care interventions to prevent tobacco use in children and adolescents.1 The Task Force recommends that primary care clinicians provide interventions, including education or brief counseling, to...
CancerCare Co-Payment Assistance Foundation Launches New Technology to Provide Cancer Patients with Same-Day Approval
CancerCare® Co-Payment Assistance Foundation recently announced the launch of its new website and customer relationship management software, DiseaseTrak. Along with the implementation of DiseaseTrak, a customer-service platform, the Foundation will now provide same-day determination and...
California Stem Cell Agency Awards More than $40 Million in New Research Grants, including Funds for Prostate Cancer Research
The California Institute for Regenerative Medicine recently announced approval by the agency’s governing Board, the Independent Citizens Oversight Committee, of $40 million in funding for researchers at 10 institutions as part of its Early Translational IV Research awards. Among the institutions...
SIDEBAR: Expect Questions From Your Patients
Physicians and patients should engage in open discussion” about the complex issues of cancer screening, overdiagnosis, and overtreatment, according to a report from the chairs of a National Cancer Institute working group tasked with developing a strategy to improve the current approach to cancer...
Tackling Overdiagnosis and Overtreatment, by Words and by Deeds
The complexity of the pathologic condition called cancer,” according to a Viewpoint article in the Journal of the American Medical Association,1 “complicates the goal of early diagnosis.” Failure to recognize that cancers are heterogeneous, and that not all progress to metastases and death, can...
Genitourinary Cancer Expert Walter M. Stadler, MD, Named Section Chief of Hematology/Oncology at the University of Chicago Medicine
Walter M. Stadler, MD, an authority on prostate, kidney, bladder, and testicular cancers, has been named Chief of the Section of Hematology/Oncology at the University of Chicago Medicine. This position became effective August 15, 2013. Dr. Stadler, the Fred C. Buffet Professor of Medicine and...
The Oncologist as Author: On Guiding Patients Through Cancer
When Tumor Is the Rumor and Cancer Is the Answer is the guidebook to cancer that Kevin P. Ryan, MD, FACP, COL, USAF (ret) wished his patients had during his 30 years of practicing oncology. The book, recently published by AuthorHouse, is an authoritative, inspiring, and even philosophical guide for ...
St. Jude Children's Research Hospital Recognizes Childhood Cancer Awareness Month
Childhood cancer remains the leading cause of death by disease among young Americans. September marks Childhood Cancer Awareness Month, a time to highlight efforts to reduce the disease’s toll on children. At St. Jude, the past year has brought advances in understanding and treating childhood...
Oncology Meetings
September Inflammation, Microbiota, and CancerSeptember 19-20 • Bethesda, MarylandFor more information: ncifrederick.cancer.gov/events/microbiota/agenda.asp Continuum Cancer Centers of New York Conference on Quality of Care in OncologySeptember 20 • New York, New YorkFor more information:...
ASCO Launches New Site to Seek Feedback from Cancer Community on Clinical Practice Guidelines
ASCO has launched a new wiki site to engage the cancer community in its clinical practice guideline development process. The new site will provide oncologists, practitioners and patients with an opportunity to provide feedback or submit evidence on individual published guidelines and can be...
The Trials and Tribulations of a Revolutionary Cancer Drug
A modest brass plaque above a booth in the Eagle Pub in Cambridge, notes, “On this spot, on February 28, 1953, Francis Crick and James Watson declared the discovery of DNA with these words: ‘We have discoverewd the secret of life.’” Announcing a major scientific advance over a pint of ale is a far...
The Direction of Immunotherapy Over the Next Decade
The use of immunotherapy to target malignant cells in a variety of cancers—especially the PD-1 inhibitors lambrolizumab and nivolumab in the treatment of metastatic melanoma and the anti–PD-L1 agent MPDL3280A in the treatment of melanoma and lung, kidney, colorectal, and gastric cancers—made...
Final Publication of IOM Report on Learning Health Systems Available
The Institute of Medicine (IOM) has issued the final publication of its report, Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. ASCO continues to support the IOM report’s core recommendations for establishing a “learning health system” in the United States and...
Conquering Cancer by Encouraging Diversity in the Field of Oncology
As the Conquer Cancer Foundation Grants and Awards Program has grown over the last 30 years, so has its purpose. Not only does the Grants and Awards Program support young researchers, foster mentoring relationships, and improve the quality of cancer care around the world, it also works to increase...
Communicating the Promise Science Offers to Society
ASCO President Clifford Hudis, MD, FACP, will be serving during a particularly notable year: 2014, the Society’s 50th anniversary. This occasion brings with it much to reflect on, from the advances in the field of oncology to the growth of ASCO’s influence, but Dr. Hudis takes a moment to simply...
Order Updated ASCO Answers Fact Sheets for Your Office or Waiting Room
ASCO Answers fact sheets give a one-page introduction to more than 40 types of adult and childhood cancers, as well as types of treatments and side effects. Each fact sheet provides an overview of the topic, a list of helpful terms, and a list of questions to ask the doctor. Download the fact...
Sustainable Growth Rate Bill Advances in the House
The U.S. House Energy and Commerce Committee has unanimously approved the Medicare Patient Access and Quality Improvement Act of 2013, which replaces Medicare’s sustainable growth rate formula. The law would provide 5 years of stable Medicare payments beginning in 2014, with reimbursement rates...
